In vitro selection of macrocyclic peptide inhibitors containing cyclic γ2,4-amino acids targeting the SARS-CoV-2 main protease.
Miura T. et al, (2023), Nat Chem, 15, 998 - 1005
Accelerating drug target inhibitor discovery with a deep generative foundation model.
Chenthamarakshan V. et al, (2023), Sci Adv, 9
Turning high-throughput structural biology into predictive inhibitor design.
Saar KL. et al, (2023), Proc Natl Acad Sci U S A, 120
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.
Brewitz L. et al, (2023), J Med Chem, 66, 2663 - 2680
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.
Malla TR. et al, (2022), J Med Chem, 65, 7682 - 7696
Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.
Brewitz L. et al, (2022), ChemMedChem, 17
Expanding the Repertoire of Low-Molecular-Weight Pentafluorosulfanyl-Substituted Scaffolds.
Jose A. et al, (2022), ChemMedChem, 17
Studies on the Reactions of Biapenem with VIM Metallo β-Lactamases and the Serine β-Lactamase KPC-2.
Lucic A. et al, (2022), Antibiotics (Basel), 11
Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-CoV-2 Main Protease.
Thun-Hohenstein STD. et al, (2022), ChemMedChem, 17
Discovery of SARS-CoV-2 Mpro peptide inhibitors from modelling substrate and ligand binding.
Chan HTH. et al, (2021), Chem Sci, 12, 13686 - 13703
Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.
Redhead MA. et al, (2021), Sci Rep, 11
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.
Redhead MA. et al, (2021), Sci Rep, 11
Faropenem reacts with serine and metallo-β-lactamases to give multiple products.
Lucic A. et al, (2021), Eur J Med Chem, 215
Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 Mpro inhibitors.
Malla TR. et al, (2021), Chem Commun (Camb), 57, 1430 - 1433
Allosteric Inhibition of the SARS-CoV-2 Main Protease: Insights from Mass Spectrometry Based Assays*.
El-Baba TJ. et al, (2020), Angew Chem Int Ed Engl, 59, 23544 - 23548
Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors
Boby ML. et al, (2020)
Allosteric Inhibition of the SARS-CoV-2 Main Protease: Insights from Mass Spectrometry Based Assays
El-Baba TJ. et al, (2020), Advanced Materials, 132, 23750 - 23754
Targeting the Mycobacterium tuberculosis transpeptidase LdtMt2 with cysteine-reactive inhibitors including ebselen.
de Munnik M. et al, (2019), Chem Commun (Camb), 55, 10214 - 10217
Non-Hydrolytic β-Lactam Antibiotic Fragmentation by l,d-Transpeptidases and Serine β-Lactamase Cysteine Variants.
Lohans CT. et al, (2019), Angew Chem Int Ed Engl, 58, 1990 - 1994